ClinicalTrials.gg
RecruitingNCT06471959Updated Jun 24, 2024

Psychedelic-assisted Group Program for First Responders

A Phase 1/2 interventional study of Psilocybin in Psilocybin and Psychotherapy, Group, sponsored by Empower Research Inc. Recruiting at 1 site in Canada. Open to participants aged 19 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-06-24.

Sponsored by Empower Research Inc · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 4 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
19 Years to 65 Years
Sex
All
01

Study summary

This study is a two-group feasibility study of oral psilocybin combined with a 12-week group-based program, customized for firefighters. Trained facilitators will help create a trauma-informed space for the group (n = 6-8) to thrive and promote cognitive resilience. The topics covered throughout the 12 weeks include breath-work, mindfulness, self-compassion, embodiment, and Internal Family Systems work.

Group 1 (control): 12-week group-based program, with a breathwork day at week 10

Group 2 (intervention): 12-week group-based program, with a 10mg dose of psilocybin (PEX010) at Week 10

Assessment timepoints:

  • Baseline
  • Mid-program (Week 6)
  • End of program (Week 12)
  • 6-month follow up
Read the detailed description

All participants will undergo a 12-week, group-based program (one session per week, for 12 weeks). The first group session, as well as the Week 10 session will occur in-person. The remainder of the sessions will occur remotely. Each week, trained facilitators will help create a trauma-informed safe space for the group to thrive and promote cognitive resilience. The topics covered throughout the 12-week program include breath-work, mindfulness, self-compassion, embodiment, and Internal Family Systems work.

During Week 10, participants will be provided with either psilocybin (active group) or complete a breathwork day (control group). For participants randomized to the active group, they will receive 10mg of psilocybin on Week 10. A clinician certified and trained in the therapeutic use of psilocybin will be on site for participants in the psilocybin group. During the dosing session, the clinicians will respond to whatever needs arise. This may include escorting them to the bathroom, giving them a drink of water. At least two staff (one facilitator and one clinician) will be on site during dosing days.

The dose will be administered in clear capsules with approximately 500ml of water. Aside from the dose provided, the weekly session will continue as usual, with a focus on breath-work, embodiment, and gentle movement on dosing days.

Psilocybin in the study comes in the form of the study drug, PYEX. PYEX is a drug substance which is a partially purified fraction of the extract of Psilocybe cubensis mushroom fruiting bodies. It is a mixture of indole alkaloids, other mushroom fruiting body components and stabilization excipients. The major indole alkaloids present include psilocybin and psilocin (dephosphorylated psilocybin). PEX010 is a capsule for oral administration and is manufactured with PYEX (12.5-14.0% psilocybin), excipients, and HPMC (hydroxypropyl methyl cellulose) capsules.

02

Conditions studied

  • Psilocybin
  • Psychotherapy, Group
03

In context

Lead sponsor

Empower Research Inc is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, 19 to 65 years of age
  • Must be a first responder, any work status (Employed full-time or part-time, Off-work, Retired, Volunteer)
  • Fluent in English
  • Able to understand the form, study procedures and willing to participate in study
  • Clinically diagnosed with a mental health condition such as:

    1. Depression
    2. Chronic anxiety
    3. Obsessive-compulsive disorder
    4. PTSD
    5. Unresolved grief
    6. Adjustment Disorder
    7. Acute Stress Disorder
  • Stable dose of medications for the last three months, with no changes anticipated for the duration of the study
  • Medical clearance by the Investigator (MD) prior to study enrollment
  • Willing and able to attend two in-person sessions throughout the 12-week program, in addition to remote sessions
  • Concurrent therapy is allowed if the type and frequency of the therapy has been stable for at least two months prior to screening and is expected to remain stable during participation in the study.
  • Agree to consume approximately the same amount of caffeine-containing beverage (e.g., coffee, tea) that he/she consumes on a usual morning, before arriving at the research unit on Week 10. If the participant does not routinely consume caffeinated beverages, he/she must agree not to do so on Week 10.
  • Agree that for one week before the drug sessions, he/she will refrain from taking any nonprescription medication, nutritional supplement, or herbal supplement (specifically SAM-e, 5-HTP, L-tryptophan, St John's Wort) except when approved by the study Investigator. Exceptions will be evaluated by the Investigator and may include acetaminophen, non-steroidal anti-inflammatory drugs, and common doses of vitamins and minerals.
  • Agree to refrain from consuming alcohol within two days prior to the Week 10 visit.
  • Agree not to take any "as needed" medications on the morning of the Week 10 visit.
  • Agree to use of highly effective methods of during the study (females)
  • Normal (BMI 18.5-24.9)

Exclusion criteria

Exclusion Criteria:

  • Current or past history of schizophrenia, psychotic disorder (unless substance induced or due to a medical condition), bipolar disorder, delusional disorder, dissociative disorder, paranoid personality disorder, schizoaffective disorder, borderline personality disorder, anorexia nervosa, bulimia nervosa or substance abuse, as assessed by medical history
  • Presence of active psychotic symptoms
  • Currently diagnosed psychotic disorder in first-degree relatives, not including psychotic disorders secondary to an apparent medical reason, e.g. brain injury, dementia, or lesions of the brain, as assessed by medical history.
  • Diagnosis of dementia or delirium
  • Risk of suicide as determined by the Investigator
  • Significantly intrusive PTSD as determined by the Investigator
  • Extreme emotional lability can be disruptive to the group milieu and is a relative exclusion criterion
  • Uncontrolled cardiopulmonary disease, cardiovascular disease, or hypertension
  • Any other cardiovascular, pulmonary, gastrointestinal, hepatic, renal, vascular or any other major concurrent illness that, in the opinion of the Investigator, may interfere with the interpretation of the study results or constitute a health risk for the participant if he/she takes part in the study
  • Psychoactive substance use (MDMA, psilocybin, LSD) within the previous two months.
  • If female and of : pregnant, suspected or planning to become pregnant during the study
  • Participation in another clinical trial (currently or within the last 30 days)
  • Current use of rifamycins (rifampin, rifabutin, rifapentine), anticonvulsants (carbamazepine, phenytoin, phenobarbital), nevirapine, efavirenz, taxol, dexamethasone); cytochrome P450 Inhibitors - including all protease inhibitors, verapamil, diltiazem, itraconazole, ketoconazole, erythromycin, clarithromycin, azithromycin, and troleandomycin; ergot alkaloids, pimozide, midazolam, triazolam, lovastatin, simvastatin, fentanyl, warfarin, metoprolol, propranolol, buspirone, tramadol, selegiline, sumatriptan.
  • Current use of inhibitors of UGT1A9 and 1A10, monoamine oxidase inhibitors (MAOIs), Tricyclic antidepressants, aldehyde dehydrogenase inhibitors (ALDHs) and alcohol dehydrogenase inhibitors (ADHs).
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    Active Group

    All participants will undergo a 12-week, group-based program (one session per week, for 12 weeks). The first group session, as well as the Week 10 session will occur in-person. The remainder of the sessions will occur remotely. Each week, trained facilitators will help create a trauma-informed safe space for the group to thrive and promote cognitive resilience. The topics covered throughout the 12-week program include breath-work, mindfulness, self-compassion, embodiment, and Internal Family Systems work. During Week 10, participants will be provided with either psilocybin (active group) or complete a breathwork day (control group). For participants randomized to the active group, they will receive 10mg of psilocybin on Week 10. A clinician certified and trained in the therapeutic use of psilocybin will be on site for participants in the psilocybin group.

    Drug: Psilocybin

Interventions

  • Psilocybin in the study comes in the form of the study drug, PYEX. PYEX is a drug substance which is a partially purified fraction of the extract of Psilocybe cubensis mushroom fruiting bodies. It is a mixture of indole alkaloids, other mushroom fruiting body components and stabilization excipients. The major indole alkaloids present include psilocybin and psilocin (dephosphorylated psilocybin). PEX010 is a capsule for oral administration and is manufactured with PYEX (12.5-14.0% psilocybin), excipients, and HPMC (hydroxypropyl methyl cellulose) capsules.

    Also known as: PEX010

06

What researchers measure

Primary outcomes

  1. Target recruitment rate

    A minimum recruitment rate of 70% of our target of 36 individuals within 6 months

    Time frame: Within 6 months

  2. Retention rate

    Retention rate of 90% at study completion

    Time frame: Study Completion (8 months)

  3. Adherence to schedule

    Adherence to scheduled study visits at a rate of 90% or higher at study completion.

    Time frame: Through Study completion (8 months)

Secondary outcomes

  1. Scores on the GAD-7 Anxiety Scale

    Scores on the GAD-7 Anxiety scale will be evaluated using a two-way mixed effects ANOVA with a between factor of GROUP and a within factor of TIME to determine the effect of the psilocybin and control interventions on symptoms of anxiety in firefighters. The scale reports scores with a lowest value of 0 representing "Not at all" experiencing the symptoms of what is asked in the questions. The highest score of 3 represents "Nearly every day" experiencing the symptoms of what is asked in the questions.

    Time frame: Study Completion (8 months)

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2025; primary completion for Jul 2025, 6 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2023
First posted
Jun 24, 2024
StartEst.
Jan 1, 2025
Primary completionEst.
Jul 1, 2025
CompletionEst.
Sep 1, 2025
Last update
Jun 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06471959
Lead sponsor
Empower Research Inc
Collaborators
Empower Psychedelics, Centre for Neurology Studies, Canada, Mitacs
Responsible party
Sponsor
First posted
Jun 24, 2024
Start date
Jan 1, 2025 (estimated)
Primary completion
Jul 1, 2025 (estimated)
Completion
Sep 1, 2025 (estimated)
Last update
Jun 24, 2024

Study contacts

Natasha Campbell, MSc
Contact
natashacampbell@healthtechconnex.com
1-778-874-7758
Jonathan Hill
Contact
jon@empresearch.co
1-604-897-9115
Reginald Peters, MD
principal investigator · University of British Columbia (Clinical Assistant Professor)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Psilocybin

Start the discussion